Last Updated: 16 June 2026
Australian healthtech company Everlab has closed an oversubscribed AU$65 million Series A funding round, backed by some of the most active venture investors in Australia and Europe. The Melbourne-based startup, founded in 2023 by Marc Hermann, Dr. Steven Lu, Sam Kothari, and Anshul Jain, has built a platform that connects diagnostics, doctors, and AI-guided care in a single app, with the goal of catching health problems before they become serious.
Most healthcare systems are set up to treat people once they get sick. A patient notices a symptom, books an appointment, gets referred to a specialist, and waits. At each step, records often stay with the provider who created them rather than following the patient through the system. As a result, conditions that could have been identified early, and addressed at lower cost, go undetected for longer than they should. According to the OECD, public spending on preventive healthcare across member countries sits at just 3% of total health expenditure, even as the cost of managing chronic disease keeps climbing.
The round was led by Australian venture capital firm Airtree Ventures, with participation from European firm Plural and existing investors Left Lane Capital and b2venture. Angel investors also joined, among them Australian Test cricket captain Pat Cummins.
The core problem Everlab is trying to address is coordination. A patient's diagnostic results live in one place, telehealth records in another, and data from wearable devices rarely reaches a clinician at all. Providers treat people based on incomplete information, and patients are left to fill the gaps themselves.
Everlab brings these pieces together in one place. The platform connects to more than 1,850 health provider locations, works with over 180 active clinicians, and supports more than 30 different wearable devices. Every month, it processes more than 200,000 health reports.
The company says its results reflect what happens when health data is consolidated and reviewed systematically. Of the more than 21 million biomarker test results processed so far, over 25% of members have had findings flagged that the standard healthcare system had not picked up. In other words, a significant share of users had conditions that were going undetected.
"The existing system is fragmented, handing patients between providers and hoping the information follows. We built Everlab to hold the full picture, surface health blind spots and coordinate what needs to happen next—from targeted screenings to personalized health plans—helping more people live longer, healthier lives."
Marc Hermann, Co-founder and CEO of Everlab
The global market for preventive healthcare technologies and services is projected to grow from USD 366 billion in 2025 to USD 741 billion by 2031, a compound annual growth rate of over 12%. The shift is driven by employers, insurers, and individuals all spending more on identifying health risks early rather than treating disease later.
Australia is dealing with its own version of this pressure. The government's National Preventive Health Strategy targets at least 5% of total health spending directed toward prevention by 2030. In 2023–24, that figure stood at just 2.9%, according to the Australian Institute of Health and Welfare. An aging population and rising private insurance costs are also pushing more Australians to take a more active role in managing their health.
Plural's Carina Namih, who joined the round as a new investor, explained what set Everlab apart from previous attempts at owning the patient journey.
"Every company that has tried to own the patient journey has ended up either selling doctor time by the minute or reselling lab tests with thin margins. Everlab is building the layer above both: the system that interprets and coordinates your health data over time rather than capturing a single transaction. The fact that they've already proven their model operationally in Australia, at scale, is what convinced me this is the version that genuinely works."
Carina Namih, Partner at Plural
The new funding will go toward building out Everlab's clinical and technology infrastructure and expanding internationally. The United Kingdom is the first planned market outside Australia and New Zealand. Everlab describes the broader opportunity it is targeting as a $10 trillion global consumer healthcare market.
The company is also building a business-to-business operation alongside its consumer product. Corporate clients including Boston Consulting Group, BHP, and Bain & Company have used Everlab to provide preventive health programs to their employees. Serving both individual members and employers gives the company more than one route to growth.
"Our patient base reflects the broader Australian population, and earning their trust to hold decades of their health data is the foundation everything else runs on. Our goal is to cut a new path for primary care globally, proving that deep patient engagement and first-class preventative care don't just improve outcomes, it reduces the lifetime cost of care for everyone."
Dr. Steven Lu, Chief Medical Officer of Everlab
Everlab was founded in Melbourne in 2023. CEO Marc Hermann previously co-founded Foodspring, a nutrition company acquired by Mars in 2019. Dr. Steven Lu leads the clinical side of the business. Anshul Jain and Sam Kothari complete the founding team, covering product, technical, and operational functions.
Members pay through an annual subscription that includes comprehensive health profiling, a customized diagnostic suite, access to a personal doctor, and care plans delivered through a mobile app. The diagnostic process covers blood tests, imaging, wearable device integrations, and continuous glucose monitoring. All of this feeds into a shared health record that clinicians and the platform's AI tools can work from together. Since launch, Everlab has completed more than 40,000 consultations for over 20,000 patients across Australia and New Zealand.
Everlab has raised capital in three stages. In December 2023, b2venture led a AU$3 million pre-seed round, with Ten13, AfterWork, Flying Fox, and several angel investors, including founders of Go1 and Aconex, participating alongside.
A AU$15 million seed round followed in July 2025, led by Left Lane Capital, a New York and London-based firm managing approximately $2.5 billion in assets. AfterWork Ventures also took part in that round.
The Series A brings total funding to approximately AU$83 million. Airtree Ventures, which led the round, manages around AU$2 billion in assets and has backed companies including Canva, Linktree, and Employment Hero.
"The more time we spent with the Everlab team, the more convinced we became that they're building a generational health business. With a world-class product and growing at a pace we rarely see, they're already the leader in Australia and we're backing them to do the same globally."
John Henderson, Partner at Airtree Ventures
